Fritextsökning
Artiklar per år
Innehållstyper
-
Discovery of new role for leukemia gene
Martin Bergö and his colleagues have studied two gene variants that often occur in acute leukemias. One gene codes for the protein RAS, which accelerates cell division in several cancers.
-
VTT in brief
VTT is a broad science cluster with research within applied materials, chemical and biochemical processes, energy, industrial systems management, information and communication technologies, microtechnology and electronics.
-
Mingling do's and don'ts
Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, networking is about meeting and talking to people face-to-face," says mingling expert Mia Forsgren at Begriplig.
-
Gabor Fischer, Distribution Sales Manager Europe, Ismatec
Why are you going to Scanlab+Biotech Forum?
-
Energiansvarig bland neutroner
Thomas Parker kommer att ansvara för arbetet med att energieffektivisera synkrotronljusanläggningen ESS Scandinavia.
-
Här blir innovationer business
Som en del i regeringens strategi för entreprenörskap startas två spetsutbildningar inom entreprenörskap och innovation. Utbildningarna hamnar i Göteborg och i Lund.
-
Biopharma vinner pris
- En enastående affärsmodell har resulterat i starka bedrifter, säger Shrikanth S, arbetsledare för affärer och finans på Frost & Sullivan.
-
Ledarbyte på Biotech Sweden
Chefredaktören för Nordens största nyhetstjänst inom life science går vidare till en helt ny bransch.
-
Symphogenchef får toppuppdrag
Den danske vetenskapsministern Helge Sander har utnämnt fyra nya ledamöter till Højteknologifondens styrelse. Alla är kvinnor och tre har ledande life scienceposter.
-
Hon leder Semcons nya satsning
Semcon breddar sin verksamhet till att också erbjuda tjänster inom FoU. Kvinnan som basar för verksamheten kommer närmast från Biovitrum.
-
Novo Seeds förstärker
Bobby Soni är ny medarbetare vid den danska investeraren, som satsar på väldigt tidiga utvecklingsprojekt.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Pfizer lays a chunky bid on Wyeth
that may lead to lay-offs of some 8,000 persons.
-
Danisco strengthens its IP team
Danisco's division Genencor has appointed a new Vice President of Intellectual Property Strategy and Chief IP Counsel.
-
Medicult needs a word of advice
Medicult Board retains advisers, regarding the previous offer from Vitrolife.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
Metabolic pro heads prefect post
The dean of the Department of Biomedicine at the Sahlgrenska Academy has appointed a new assistant prefect.
-
Swedish nanotech crosses the Atlantic
Genovis signs distribution agreement Finnzymes in US.
-
Infidelity produces faster sperms
Until now, it has been difficult to prove that fast-swimming sperms have an advantage when it comes to fertilizing an egg.
-
Dako appoints new CEO
The Danish cancer therapeutic company Dako has appointed a new CEO after Patrik Dahlén.
-
Abbott expands by acquisition
An acquisition gives Abbott a leadership position in another large and growing medical device segment.
-
Finnish Innovation Fund gets new leader
The Supervisory Board of the Finnish Innovation Fund Sitra has appointed members of the Board, including a new president.
-
Pharma is a safe market
Pharma is the best industry to invest in. That states leaders from risk capital companies, interviewed by the Economist Intelligence Unit.